Abstract and Introduction
Introduction
Pandemic and epidemic influenza infections lead to significant morbidity and mortality annually despite various vaccination and treatment options. Baloxavir marboxil, approved by the Food and Drug Administration (FDA) on October 24, 2018, offers a novel approach to treatment of acute uncomplicated influenza in adolescents and adults.[1] The drug received Priority Review by the FDA in June 2018 and its phase II and III trial data were published in the New England Journal of Medicine in September 2018.[2]
Pediatr Pharm. 2019;25(2) © 2019 University of Virginia
